DYN insider filings
Dyne Therapeutics, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-16. Screen DYN transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 9 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing by 1 insider — 2,500 shares, $40,000 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 9 legs across 7 filings by 4 insiders — 22,117 shares, $421,679 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 2.
- Largest priced transaction: sale of 5,658 shares @ $18.88 ($106,823) by Cox John, filed 2026-09-08.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Cox John — CEO & President, Director | 2 | — | 2 legs · 11,171 sh · $199,552 | — |
| Kerr Douglas — Head of R&D and CMO | 3 | — | 3 legs · 7,639 sh · $159,345 | 2 |
| Posner Brian S — Director | 1 | 1 leg · 2,500 sh · $40,000 | — | — |
| Lucera Erick — Chief Financial Officer | 1 | — | 1 leg · 1,991 sh · $33,489 | — |
| Friedl-Naderer Johanna — Chief Commercial Officer | 2 | — | 3 legs · 1,316 sh · $29,293 | — |
Recent insider filings — Dyne Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-16 | 4 | Lucera Erick — Chief Financial Officer | Sale (S): 1,991 @ $16.82 | EDGAR |
| 2026-11-16 | 4 | Cox John — CEO & President, Director | Sale (S): 5,513 @ $16.82 | EDGAR |
| 2026-11-16 | 4 | Kerr Douglas — Head of R&D and CMO | Sale (S): 2,604 @ $16.82 | EDGAR |
| 2026-11-16 | 4 | Friedl-Naderer Johanna — Chief Commercial Officer | Sale (S): 231 @ $16.82 | EDGAR |
| 2026-10-22 | 4 | Kerr Douglas — Head of R&D and CMO | Grant/award (A): 8,000 @ $0 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2026-10-06 | 4 | Posner Brian S — Director | Purchase (P): 2,500 @ $16 | EDGAR |
| 2026-09-08 | 4 | Cox John — CEO & President, Director | Sale (S): 5,658 @ $18.88 | EDGAR |
| 2026-09-08 | 4 | Kerr Douglas — Chief Medical Officer | Sale (S): 3,745 @ $24.35 · Sale (S): 1,290 @ $18.88 | EDGAR |
| 2026-09-08 | 4 | Friedl-Naderer Johanna — Chief Commercial Officer | Sale (S): 900 @ $24.35 · Sale (S): 185 @ $18.88 | EDGAR |
| 2026-08-17 | 4 | Rhodes Jason P — Director | Sale (S): 268,354 @ $26.20 · Sale (S): 94,415 @ $26.20 · Sale (S): 63,643 @ $26.20 · Sale (S): 1,359,674 @ $25 · Sale (S): 478,377 @ $25 · Sale (S): 322,465 @ $25 | EDGAR |
| 2026-08-17 | 4 | Friedl-Naderer Johanna — Chief Commercial Officer | Sale (S): 226 @ $26.28 | EDGAR |
| 2026-08-17 | 4 | Lucera Erick — Chief Financial Officer | Sale (S): 1,797 @ $26.28 | EDGAR |
| 2026-08-17 | 4 | Cox John — CEO & President, Director | Sale (S): 4,986 @ $26.28 | EDGAR |
| 2026-08-17 | 4 | Kerr Douglas — Chief Medical Officer | Sale (S): 1,556 @ $26.28 | EDGAR |
| 2026-07-29 | 4 | Kersten Dirk — Director | Sale (S): 256,072 @ $25.50 · Sale (S): 5,388 @ $26.04 | EDGAR |
| 2026-07-08 | 4 | Rhodes Jason P — Director | Sale (S): 253,039 @ $22.79 · Sale (S): 127,182 @ $22.79 · Sale (S): 100,019 @ $22.79 · Sale (S): 124,379 @ $23.17 · Sale (S): 29,587 @ $23.62 · Sale (S): 62,543 @ $23.17 · +4 more | EDGAR |
| 2026-06-30 | 4 | Rhodes Jason P — Director | Sale (S): 162,954 @ $21.28 · Sale (S): 81,903 @ $21.28 · Sale (S): 64,411 @ $21.28 · Sale (S): 102,969 @ $21.14 · Sale (S): 51,756 @ $21.14 · Sale (S): 40,702 @ $21.14 | EDGAR |
| 2026-06-26 | 4 | Lucera Erick — Chief Financial Officer | Sale (S): 2,362 @ $20.37 | EDGAR |
| 2026-06-26 | 4 | Rhodes Jason P — Director | Sale (S): 77,855 @ $21.13 · Sale (S): 39,131 @ $21.13 · Sale (S): 30,774 @ $21.13 · Sale (S): 50,530 @ $21.02 · Sale (S): 25,397 @ $21.02 · Sale (S): 19,973 @ $21.02 · +3 more | EDGAR |
| 2026-06-24 | 4 | Kersten Dirk — Director | Sale (S): 190,676 @ $20.57 · Sale (S): 71,629 @ $21.04 · Sale (S): 1,657 @ $21.47 | EDGAR |
| 2026-06-23 | 4 | Greene Barry E — Director | Grant/award (A): 57,463 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Kersten Dirk — Director | Sale (S): 37,454 @ $20.14 · Sale (S): 46,901 @ $20.07 | EDGAR |
| 2026-06-17 | 4 | Friedl-Naderer Johanna — Chief Commercial Officer | Sale (S): 145 @ $18.33 | EDGAR |
| 2026-06-17 | 4 | Kerr Douglas — Chief Medical Officer | Sale (S): 887 @ $18.33 | EDGAR |
| 2026-06-17 | 4 | Cox John — CEO & President, Director | Sale (S): 2,683 @ $18.33 | EDGAR |
| 2026-06-09 | 4 | Kersten Dirk — Director | Grant/award (A): 35,152 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Incerti Carlo — Director | Grant/award (A): 35,152 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Stehman-Breen Catherine — Director | Grant/award (A): 35,152 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Rhodes Jason P — Director | Grant/award (A): 35,152 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Lubner David Charles — Director | Grant/award (A): 35,152 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Posner Brian S — Director | Purchase (P): 2,000 @ $16.94 · Grant/award (A): 35,152 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | HURWITZ EDWARD — Director | Grant/award (A): 35,152 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Posner Brian S — Director | Purchase (P): 2,500 @ $17.48 | EDGAR |
| 2026-05-28 | 4 | Posner Brian S — Director | Purchase (P): 2,000 @ $18.21 | EDGAR |
| 2026-05-22 | 4 | Posner Brian S — Director | Purchase (P): 2,500 @ $17.12 | EDGAR |
| 2026-05-14 | 4 | Friedl-Naderer Johanna — Chief Commercial Officer | Sale (S): 228 @ $18.36 | EDGAR |
| 2026-05-14 | 4 | Kerr Douglas — Chief Medical Officer | Sale (S): 1,564 @ $18.36 | EDGAR |
| 2026-05-14 | 4 | Lucera Erick — Chief Financial Officer | Sale (S): 1,448 @ $18.36 | EDGAR |
| 2026-05-14 | 4 | Cox John — CEO & President, Director | Sale (S): 3,311 @ $18.36 | EDGAR |
| 2026-05-06 | 4 | Rhodes Jason P — Director | Sale (S): 3,136 @ $18 · Sale (S): 6,241 @ $18 · Sale (S): 61 @ $18 · Sale (S): 2,466 @ $18 · Sale (S): 3,056 @ $18.03 · Sale (S): 6,081 @ $18.03 · +6 more | EDGAR |
| 2026-04-30 | 4 | Rhodes Jason P — Director | Sale (S): 59,870 @ $18.38 · Sale (S): 119,115 @ $18.38 · Sale (S): 1,170 @ $18.38 · Sale (S): 47,082 @ $18.38 · Sale (S): 26 @ $19 · Sale (S): 52 @ $19 · +2 more | EDGAR |
| 2026-04-28 | 4 | Lubner David Charles — Director | Gift (G): 53,625 @ $0 | EDGAR |
| 2026-04-27 | 4 | Rhodes Jason P — Director | Sale (S): 19,261 @ $19.19 · Sale (S): 38,322 @ $19.19 · Sale (S): 377 @ $19.19 · Sale (S): 15,148 @ $19.19 · Sale (S): 36,345 @ $18.48 · Sale (S): 72,310 @ $18.48 · +6 more | EDGAR |
| 2026-04-23 | 4 | Kersten Dirk — Director | Sale (S): 8,300 @ $20.01 · Sale (S): 2,652 @ $20.00 | EDGAR |
| 2026-04-22 | 4 | Rhodes Jason P — Director | Sale (S): 71,676 @ $20.06 · Sale (S): 142,604 @ $20.06 · Sale (S): 1,401 @ $20.06 · Sale (S): 56,368 @ $20.06 · Sale (S): 71,499 @ $19.51 · Sale (S): 142,253 @ $19.51 · +10 more | EDGAR |
| 2026-04-21 | 4 | Kersten Dirk — Director | Sale (S): 211,974 @ $20.29 · Sale (S): 125,274 @ $20.07 | EDGAR |
| 2026-04-17 | 4 | Kersten Dirk — Director | Sale (S): 81,840 @ $20.27 · Sale (S): 11,116 @ $21.10 · Sale (S): 6,657 @ $20.06 | EDGAR |
| 2026-04-03 | 4 | Lucera Erick — Chief Financial Officer | Sale (S): 5,727 @ $18.64 | EDGAR |
| 2026-04-01 | 4 | Posner Brian S — Director | Purchase (P): 2,000 @ $17.08 | EDGAR |
| 2026-03-13 | 4 | Posner Brian S — Director | Purchase (P): 2,000 @ $19.35 | EDGAR |
Recent 8-K events — Dyne Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-29 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-29 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-22 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-20 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-06-22 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-17 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | EDGAR |
| 2026-06-08 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-06-03 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=DYN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs